Phase II trial and cost analysis of XXXX in advanced @entity1149 : a Southwest Oncology Group study.

@entity1 @entity2353 @entity1149 @entity900 @entity2879 @entity12085
BACKGROUND: @entity12085 is a novel @entity2353 with broad spectrum pre-clinical activity and was chosen for study in @entity1 with incurable @entity1149 . The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. METHODS: Twenty-three @entity1 with metastatic @entity1149 were treated with @entity12085 . @entity12085 was administered as a 72 hour continuous infusion at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for @entity1 treated in Springfield, MO. RESULTS: There were no responses (0%, 95% confidence interval = 0-15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 @entity1 treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of @entity900 and @entity2879 . There were no significant differences in costs for @entity1 treated with the investigational agent as compared with conventional chemotherapy. CONCLUSIONS: @entity12085 has no demonstrable activity in @entity1 with metastatic @entity1149 . Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.
